Log in

NASDAQ:OVIDOvid Therapeutics Stock Price, Forecast & News

$7.02
-0.12 (-1.68 %)
(As of 08/11/2020 04:00 PM ET)
Add
Compare
Today's Range
$6.76
Now: $7.02
$7.42
50-Day Range
$6.32
MA: $7.16
$7.91
52-Week Range
$1.74
Now: $7.02
$9.40
Volume507,150 shs
Average Volume957,130 shs
Market Capitalization$384.37 million
P/E RatioN/A
Dividend YieldN/A
Beta2.11
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome. It is also developing OV935, a drug candidate, which has completed Phase 1b/2a trial for rare epileptic encephalopathies. The company has collaboration agreement with Takeda Pharmaceutical Company Limited; and a license agreement with H. Lundbeck A/S. Ovid Therapeutics Inc. was founded in 2014 and is headquartered in New York, New York.
Read More
Ovid Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.59 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OVID
CUSIPN/A
Phone646-661-7661

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.46 per share

Profitability

Net Income$-60,460,000.00

Miscellaneous

Employees59
Market Cap$384.37 million
Next Earnings Date11/13/2020 (Estimated)
OptionableNot Optionable
$7.02
-0.12 (-1.68 %)
(As of 08/11/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OVID News and Ratings via Email

Sign-up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Ovid Therapeutics (NASDAQ:OVID) Frequently Asked Questions

How has Ovid Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Ovid Therapeutics' stock was trading at $2.68 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, OVID shares have increased by 161.9% and is now trading at $7.02.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Ovid Therapeutics?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Ovid Therapeutics
.

When is Ovid Therapeutics' next earnings date?

Ovid Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, November 13th 2020.
View our earnings forecast for Ovid Therapeutics
.

How were Ovid Therapeutics' earnings last quarter?

Ovid Therapeutics Inc (NASDAQ:OVID) announced its quarterly earnings results on Monday, August, 10th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.36) by $0.05.
View Ovid Therapeutics' earnings history
.

What price target have analysts set for OVID?

8 Wall Street analysts have issued 1-year target prices for Ovid Therapeutics' shares. Their forecasts range from $9.00 to $21.00. On average, they anticipate Ovid Therapeutics' stock price to reach $13.33 in the next twelve months. This suggests a possible upside of 89.9% from the stock's current price.
View analysts' price targets for Ovid Therapeutics
.

Has Ovid Therapeutics been receiving favorable news coverage?

Headlines about OVID stock have trended somewhat positive recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ovid Therapeutics earned a coverage optimism score of 1.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days.
View the latest news about Ovid Therapeutics
.

Are investors shorting Ovid Therapeutics?

Ovid Therapeutics saw a decline in short interest during the month of February. As of February 15th, there was short interest totaling 935,500 shares, a decline of 14.2% from the January 31st total of 1,090,000 shares. Based on an average daily trading volume, of 722,100 shares, the short-interest ratio is presently 1.3 days. Approximately 4.2% of the company's stock are sold short.
View Ovid Therapeutics' Short Interest
.

Who are some of Ovid Therapeutics' key competitors?

What other stocks do shareholders of Ovid Therapeutics own?

Who are Ovid Therapeutics' key executives?

Ovid Therapeutics' management team includes the following people:
  • Dr. Jeremy Max Levin, Chairman & CEO (Age 67, Pay $821.32k)
  • Dr. Amit Rakhit, Pres & Chief Medical Officer (Age 50, Pay $694.05k)
  • Mr. Timothy G. Daly, Exec. VP of Fin., Treasurer & Corp. Controller (Age 49, Pay $439.45k)
  • Dr. Matthew J. During, Founder & Chairman of Scientific Advisory Board (Age 63)
  • Ms. Lora Pike, Sr. Director of Investor Relations & PR

When did Ovid Therapeutics IPO?

(OVID) raised $80 million in an IPO on Friday, May 5th 2017. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

What is Ovid Therapeutics' stock symbol?

Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."

Who are Ovid Therapeutics' major shareholders?

Ovid Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.93%), Platinum Investment Management Ltd. (0.55%), UBS Group AG (0.24%), Virtus ETF Advisers LLC (0.12%), New York State Common Retirement Fund (0.07%) and SG Americas Securities LLC (0.04%). Company insiders that own Ovid Therapeutics stock include Douglas E Williams, Jeremy M Levin, Karen Bernstein and Pharmaceutical Co Ltd Takeda.
View institutional ownership trends for Ovid Therapeutics
.

Which major investors are selling Ovid Therapeutics stock?

OVID stock was sold by a variety of institutional investors in the last quarter, including Platinum Investment Management Ltd., and UBS Group AG.
View insider buying and selling activity for Ovid Therapeutics
.

Which major investors are buying Ovid Therapeutics stock?

OVID stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Virtus ETF Advisers LLC, New York State Common Retirement Fund, SG Americas Securities LLC, State Board of Administration of Florida Retirement System, Aigen Investment Management LP, Strs Ohio, and Ameritas Investment Partners Inc.. Company insiders that have bought Ovid Therapeutics stock in the last two years include Douglas E Williams, Jeremy M Levin, Karen Bernstein, and Pharmaceutical Co Ltd Takeda.
View insider buying and selling activity for Ovid Therapeutics
.

How do I buy shares of Ovid Therapeutics?

Shares of OVID can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ovid Therapeutics' stock price today?

One share of OVID stock can currently be purchased for approximately $7.02.

How big of a company is Ovid Therapeutics?

Ovid Therapeutics has a market capitalization of $384.37 million. The company earns $-60,460,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis. Ovid Therapeutics employs 59 workers across the globe.

What is Ovid Therapeutics' official website?

The official website for Ovid Therapeutics is www.ovidrx.com.

How can I contact Ovid Therapeutics?

Ovid Therapeutics' mailing address is 1460 Broadway Suite 15044, New York NY, 10036. The company can be reached via phone at 646-661-7661 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.